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Abstract
Introduction Anti-PM/Scl antibodies are present in sera from
patients with polymyositis (PM), systemic sclerosis (SSc), and
PM/SSc overlap syndromes. The prevalence of antibodies
against the 75- and 100-kDa PM/Scl proteins and their clinical
associations have not been studied in SSc patients in detail so
far but could provide a valuable tool for risk assessment in these
patients. Furthermore, it remains speculative whether
commercially available test systems detecting only anti-PM/Scl-
100 antibodies are sufficient in SSc patients.
Methods Two hundred eighty sera from SSc patients, patients
with other connective tissue diseases (n = 209), and healthy
blood donors (n = 50) were analyzed for the presence of anti-
PM/Scl-75 and anti-PM/Scl-100 antibodies by means of line
immunoblot assay. For the SSc patients, possible associations
between both subsets of anti-PM/Scl antibodies with clinical
and laboratory findings were studied.
Results The determination of anti-PM/Scl reactivity revealed a
diagnostic sensitivity of 12.5% and a specificity of 96.9% for
SSc. Among anti-PM/Scl-positive SSc patients, 10.4% and
7.1% were positive for anti-PM/Scl-75 and anti-PM/Scl-100
antibodies, respectively. The highest prevalences of reactivity to
PM/Scl were detected in diffuse SSc (19.8%) and overlap
syndromes (17.6%). Patients with diffuse SSc showed mainly
an anti-PM/Scl-75 response, whereas most cases of overlap
syndromes were characterized by reactivity to both PM/Scl
antigens. The presence of anti-PM/Scl-75/100 antibodies was
associated with muscular and lung involvements as well as with
digital ulcers; pulmonary arterial hypertension was found less
frequently. Anti-PM/Scl-75 antibodies were detected more
frequently in younger and more active patients with joint
contractures. Anti-PM/Scl-100 antibodies were associated with
creatine kinase elevation; however, gastrointestinal
involvements were observed less frequently.
Conclusions Anti-PM/Scl antibodies are common in distinct
SSc subsets and are associated with several clinical symptoms.
They are directed mainly to the PM/Scl-75 antigen.
Consequently, the detection of anti-PM/Scl antibodies by tests
based only on PM/Scl-100 as an antigen source may miss a
relevant number of SSc patients positive for these antibodies.
anti-topo I: anti-topoisomerase I; CENP-B: centromere protein-B; CK: creatine kinase; DLCO-SB: predicted diffusion capacity of a single breath; 
DNSS: German Network (Deutsches Netzwerk) of Systemic Scleroderma; dSSc: diffuse systemic sclerosis; ELISA: enzyme-linked immunosorbent 
assay; EUSTAR: European Scleroderma Trials and Research; FVC: forced vital capacity; LIA: line immunoblot assay; lSSc: limited systemic sclerosis; 
mRSS: modified Rodnan skin score; PAH: pulmonary arterial hypertension; PM: polymyositis; RA: rheumatoid arthritis; RP: Raynaud phenomenon; 
SD: standard deviation; SLE: systemic lupus erythematosus; SS: Sjögren syndrome; SSc: systemic sclerosis; SScSS: systemic sclerosis sine scle-
roderma; U: units; UCTD: undifferentiated connective tissue disease.Arthritis Research & Therapy    Vol 11 No 1    Hanke et al.
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Introduction
Autoantibodies often characterize patients with distinct clini-
cal features and often have prognostic relevance in different
connective tissue diseases. Anti-PM/Scl antibodies, first
described in patients with an overlap syndrome of polymyositis
(PM) and scleroderma (systemic sclerosis [SSc]), seem to be
rare antibodies, especially when SSc patients were studied
[1]. In what is currently the largest study on the prevalence of
anti-PM/Scl antibodies using the Pittsburgh Scleroderma
Databank, only 2.5% of the SSc patients exhibited anti-PM/
Scl antibodies [2]. The low number of anti-PM/Scl-positive
patients did not allow conclusive analyses concerning associ-
ated clinical features, and the SSc patients were not classified
according to their disease subsets. However, the descriptions
of anti-PM/Scl-positive patients point to a higher prevalence of
patients with muscular involvement, supporting other investi-
gations using smaller populations or patients with myositis
[1,3-6]. An association between the presence of anti-PM/Scl
antibodies and Raynaud phenomenon (RP), arthritis, and inter-
stitial lung disease was suggested as well [5].
Anti-PM/Scl antibodies are a heterogeneous group of autoan-
tibodies directed to several proteins of the nucleolar PM/Scl
macromolecular complex. The two main autoantigenic protein
components were identified and termed PM/Scl-75 and PM/
Scl-100 based on their apparent molecular weights [7,8].
According to former studies indicating PM/Scl-100 as the
main target of the autoimmune response to PM/Scl, the major-
ity of commercially available assays use recombinant PM/Scl-
100 protein [3]. However, recent studies also suggest the
diagnostic importance of anti-PM/Scl-75 antibodies, espe-
cially when the major isoform PM/Scl-75c is used as an anti-
gen source [9,10]. The percentage of patients presenting anti-
PM/Scl-75c antibodies is supposed to exceed that for anti-
PM/Scl-100 antibodies [9]. However, analyses of larger SSc
cohorts to identify the prevalence and specificity of these anti-
bodies are missing. Furthermore, it remains elusive whether
the different antibodies reflect different SSc subsets and clin-
ical features present in these patients.
Based on the growing knowledge about the anti-PM/Scl anti-
body targets, very sensitive methods such as an enzyme-linked
immunosorbent assay (ELISA), which is based on a PM/Scl-
100-derived peptide called PM1-alpha, have been developed
[11]. In recent years, line immunoblot assay (LIA) has become
a popular technique for the simultaneous detection of several
autoantibodies. As recently shown and exemplified for the
determination of anti-topoisomerase I (anti-topo I) antibodies,
LIA provides a valuable tool as an alternative to ELISA [12].
In the present study, a large monocentric cohort of consecu-
tive SSc patients was analyzed by LIA, allowing the simultane-
ous monospecific detection of both anti-PM/Scl-75 and anti-
PM/Scl-100 antibodies. Clinical data were assessed simulta-
neously by a standardized procedure with only a limited
number of investigators. For patient assessment, we applied
criteria and strategies developed by the German Network of
Systemic Scleroderma (DNSS) and the European Sclero-
derma Trials and Research (EUSTAR) network [13-15]. By
this approach, we identified several clinical features associ-
ated with the presence of either anti-PM/Scl antibody.
Materials and methods
Classification of patients
Sera from 280 consecutive SSc patients were analyzed for the
presence of anti-PM/Scl antibodies. Patients were divided into
different subsets according to the criteria of the EUSTAR and
DNSS network [13,14]. Briefly, diffuse SSc (dSSc) and lim-
ited SSc (lSSc) were defined according to LeRoy and col-
leagues [16] and the DNSS and EUSTAR criteria based on
the maximal distribution of skin involvement during the disease
course. Overlap syndromes, including mixed connective tissue
disease, were defined as a disease occurring with clinical
aspects of SSc or main symptoms of SSc in parallel to those
of other connective tissue diseases [17]. SSc sine sclero-
derma (SScSS) was defined as described by Rodnan and
Fennel [18]. Undifferentiated connective tissue disease
(UCTD) with scleroderma features was defined as positive RP
and at least one further feature of SSc (for example, typical nail
fold capillary alterations, puffy fingers, or pulmonary hyperten-
sion) and/or detectable scleroderma-associated autoantibod-
ies without fulfilment of American College of Rheumatology
criteria [19]. By using (or applying) the criteria of LeRoy and
colleagues [16], these patients can also be classified as hav-
ing limited disease. According to these criteria, our study
included 113 patients with lSSc, 96 patients with dSSc, 51
patients with an overlap syndrome, 16 patients with UCTD,
and 4 patients with SScSS. The clinical and epidemiological
data of this cohort are presented in Table 1. As demonstrated
before, our cohort is representative of European SSc cohorts
showing similar clinical features [12]. In addition, 259 control
sera from patients with Sjögren syndrome (SS) (n = 49), sys-
temic lupus erythematosus (SLE) (n = 72), and rheumatoid
arthritis (RA) (n = 88) and from healthy blood donors (n = 50)
were analyzed. All control patients were diagnosed according
to internationally recognized criteria [20-22].
Assessment of the systemic sclerosis patients
Between January 2004 and May 2007, sera of 280 SSc
patients were collected during the clinical assessment of the
patients, stored at -20°C, and analyzed for the presence of
SSc-associated antibodies. Most patients were assessed by
one investigator (GR), who instructed the only other investiga-
tor (CSB). Both investigators participated in several training
programs of EUSTAR and DNSS for the assessment of
patients. In general, 26 clinical and laboratory findings were
assessed and analyzed as described [12-14]. Briefly, for the
evaluation of fibrotic skin changes and for the classification of
the SSc subsets, the modified Rodnan skin score (mRSS)
was used [23]. Pulmonary arterial hypertension (PAH) wasAvailable online http://arthritis-research.com/content/11/1/R22
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defined when assessed by a right heart catheter with mean
pulmonary arterial pressures of 25 mm Hg at rest and 30 mm
Hg while exercising or by the presence of a pulmonary arterial
systolic pressure of greater than or equal to 40 mm Hg and
signs of right heart failure as detected by echocardiography.
Pulmonary fibrosis was defined by evidence of fibrosis such as
bibasilar fibrosis on chest radiogram and/or by high-resolution
computed tomography scans. Lung function was assessed by
the predicted forced vital capacity (FVC) and the predicted dif-
fusion capacity of a single breath (DLCO-SB) method. Digital
ulcers were defined as a loss of both epidermis and dermis in
an area of at least 2 mm in diameter at the distal phalanx of fin-
gers. Elevation of serum creatine kinase (CK) levels was con-
sidered when they increased above normal values. Disease
activity was assessed by using the criteria of the European
Scleroderma Study Group [24]. The study was approved by
the local ethics committee (EA1/013/705). Written informed
consent was obtained from each patient.
Antibody detection by line immunoblot assay
For the detection of the different anti-PM/Scl antibodies, a pro-
file LIA was developed and provided by EUROIMMUN AG
(Lübeck, Germany). Briefly, recombinant PM/Scl-100 antigen
was expressed by Escherichia coli or by baculovirus, spanning
the major alpha helical epitope region between 231 and 245
(as described elsewhere [25]). PM/Scl-75c was expressed by
baculovirus [10]. After affinity purification, the antigens were
separately coated as lines onto nitrocellulose membrane chips
that were fixed onto a plastic strip, creating a line immu-
noassay format based on the main target antigens of anti-PM/
Scl antibodies. The LIA was additionally coated with antigens
allowing anti-topo I, anti-U1-RNP, and anti-centromere protein-
A/B (anti-CENP-A/B) antibody detection. To ensure diagnos-
tic reliability and precision, the LIA was subjected to an exten-
sive validation process. Sera from 280 SSc patients as well
259 controls were incubated according to the instructions of
the manufacturer (EUROIMMUN AG) (30-minute serum incu-
bation, washing step 1, 30-minute incubation with anti-human
IgG/alkaline phosphatase, washing step 2, and 10-minute
substrate incubation with NBT/BCIP [nitroblue tetrazolium/5-
bromo-4-chloro-3-indolyl-phosphate]). Blot strips were digital-
ized using a flatbed scanner, and band intensities were evalu-
ated by a computer program (EUROLineScan, EUROIMMUN
AG). Signal strengths of greater than 6 units (U) were consid-
ered positive, as recommended by the manufacturer. All sero-
Table 1
Clinical and demographic characteristics of the Charité cohort
dSSc lSSc SScSS Overlap UCTD All
Number 96 113 4 51 16 280
Age in yearsa 54.5 (14.7) 63.0 (11.2) 52.5 (12.9) 51 (13.2) 55.5 (10.6) 58.0 (13.3)
Duration of RP in yearsa 5 (10.2) 9.5 (12.6) 12 (21.3) 7 (8.6) 8 (9.6) 7.5 (11.3)
Duration of disease in yearsa 5 (7.7) 8 (7.0) 3.5 (6.8) 7 (7.6) 5 (10.9) 7 (7.6)
Females/males 79/17 105/8 2/2 41/10 16/0 243/37
mRSSa 11.0 (9.61) 4.0 (4.3) 1.0 (1.1) 3.0 (6.9) 0.0 (1.1) 5.0 (8.0)
Digital ulcersb 52 (54.2) 38 (33.6) 2 (50) 18 (35.2) 2 (12.5) 112 (40.0)
Lung fibrosisb 57 (59.4) 16 (14.2) 3 (75) 20 (39.2) 2 (12.5) 98 (35.0)
DLCO-SBa, % 65.3 (21.9) 78.9 (17.5) 51.1(12.8) 71.2 (21.7) 80.0 (17.1) 72.4 (20.5)
Mean FVCa, % 82.1 (18.9) 97.4 (15.2) 95.5 (30.7) 86.5 (20.5) 95.2 (18.0) 91.6 (19.0)
Contracturesb 78 (81.3) 62 (54.9) 2 (50) 27 (52.9) 3 (18.8) 172 (61.4)
PAHb 22 (22.9) 22 (19.5) 2 (50) 13(25.7) 1 (6.3) 60 (21.4)
Renal involvementb 17 (17.7) 22 (19.5) 1 (25) 14 (27.5) 2 (12.5) 56 (20.0)
Renal crisisb 10 (10.4) 3 (2.7)
n = 112
1 (25) 1 (2.0) 1 (6.3) 16 (5.7)
n = 279
Cardiac involvementb 47 (49.0) 35 (31.0) 3 (75) 25 (49) 4 (25) 117 (40.7)
Skin involvementb 94 (98.9) 105 (92.9) 3 (75) 39 (76.5) 7 (43.8) 248 (88.9)
RPb 95 (99) 110 (97.3) 4 (100) 50 (98) 13 (81.3) 272 (97.1)
aValues displayed are medians (standard deviations). bValues displayed are numbers of patients (percentages). DLCO-SB, predicted diffusion 
capacity of a single breath; dSSc, diffuse systemic sclerosis; FVC, forced vital capacity; lSSc, limited systemic sclerosis; mRSS, modified Rodnan 
skin score; PAH, pulmonary arterial hypertension; RP, Raynaud phenomenon; SScSS, systemic sclerosis sine scleroderma; UCTD, 
undifferentiated connective tissue disease.Arthritis Research & Therapy    Vol 11 No 1    Hanke et al.
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logical analyses were performed blindly by personnel unaware
of the diagnosis or the clinical characteristics of the patients.
Statistical analysis
The dataset was analyzed by means of the SPSS version 15.0
statistical package (SPSS Inc., Chicago, IL, USA) and the cal-
culation software Excel version 12 (2007) (Microsoft Corpora-
tion, Redmond, WA, USA). For the analysis of qualitative
values, chi-square and Fisher's exact tests were used. Quanti-
tative values were compared by using the Mann-Whitney U
test. P values of less than 0.05 were considered statistically
significant.
Results
Prevalences of anti-PM/Scl-75 and anti-PM/Scl-100 in 
systemic sclerosis patients depend on disease subset 
and antigen expression system
Anti-PM/Scl-75 antibodies were present in 29 SSc patients
(10.4%). Antibody reactivity against the PM/Scl-100 antigen
expressed by E. coli was detected in 20 SSc patients (7.1%).
All together, 35 out of 280 patients tested positive for anti-PM/
Scl antibodies (12.5%) (Figure 1a). When the PM/Scl-100
antigen expressed by baculovirus was used, only 11 patients
(3.9%) showed reactivity. The highest prevalences of anti-PM/
Scl antibodies were found in dSSc patients (19.8%) and in
patients suffering from overlap syndrome (17.6%) (Figure
1b,d). In contrast, anti-PM/Scl antibodies were rarely found in
patients with lSSc (3.5%) (Figure 1c). In our control group
with autoimmune diseases other than SSc (n = 259), there
were eight anti-PM/Scl-positive sera with non-overlapping
reactivities: On the one hand, reactivity to PM/Scl-100 (E. coli)
was found in 1 out of 49 patients with SS (2%) and in 3 out of
72 patients with SLE (4.2%). On the other hand, anti-PM/Scl-
75 antibodies were present in 1 patient with SLE (1.4%) and
in 3 out of 88 patients (3.4%) with RA. None of the healthy
blood donors exhibited either of these antibodies. Therefore,
anti-PM/Scl antibody detection revealed an overall specificity
for SSc of 96.9%. The specificities of anti-PM/Scl-75 and anti-
PM/Scl-100 antibodies amounted to 98.5% each. The detec-
tion of antibodies directed to the PM/Scl-100 antigen
expressed by baculovirus showed 100% specificity for SSc
patients.
Concordance of anti-PM/Scl-75, anti-PM/Scl-100, anti-
topo I, and anti-CENP-B antibodies
For further analyses, we included only the results from LIA
using PM/Scl-100 antigen expressed by E. coli and PM/Scl-
75 autoantigen expressed by baculovirus. When the 35 anti-
PM/Scl antibody-positive sera were analyzed for their subspe-
cificities (anti-PM/Scl-75 and anti-PM/Scl-100) and for further
Figure 1
The presence of different anti-PM/Scl antibodies depends on the underlying disease subset in systemic sclerosis (SSc) The presence of different anti-PM/Scl antibodies depends on the underlying disease subset in systemic sclerosis (SSc). Co-occurrence of antibod-
ies that recognize different recombinant antigens as detected by line immunoblot assay in all anti-PM/Scl-positive patients (a), in patients with dif-
fuse SSc (dSSc) (b), in patients with limited SSc (lSSc) (c), and in patients with overlap syndromes (d). anti-topo I, anti-topoisomerase I; CENP-B, 
centromere protein-B; PM, polymyositis.Available online http://arthritis-research.com/content/11/1/R22
Page 5 of 9
(page number not for citation purposes)
autoantibodies, only one patient was exclusively positive for
anti-PM/Scl-75 and six patients showed single reactivity to
PM/Scl-100 (Figure 1a). Thirteen sera showed reactivity to
both the PM/Scl-75 and the PM/Scl-100 antigen, and one of
these sera was additionally reactive to topo I. A combination of
anti-PM/Scl-75 and anti-topo I antibodies was found in
another 13 serum samples. Two patients were positive for
anti-CENP-B and anti-PM/Scl-75 antibodies. Two patients
with anti-PM/Scl-75 antibodies also exhibited anti-U1-RNP
antibodies (data not shown). When the subset of dSSc
patients was studied (Figure 1b), 18 out of 19 anti-PM/Scl-
positive sera revealed reactivity to PM/Scl-75 (94.7%).
Among these 18 sera, 12 specimens were positive for both
anti-PM/Scl-75 and anti-topo I antibodies, whereas the
remaining 6 were reactive to both PM/Scl-75 and PM/Scl-100
(including only 1 anti-topo I-positive specimen). Only 1 out of
19 anti-PM/Scl-positive sera from dSSc patients showed
reactivity to only PM/Scl-100, and this serum was also positive
for antibodies directed to CENP-B. In patients with lSSc, 1 out
of 4 anti-PM/Scl-positive patients showed positivity for PM/
Scl-100 only, 2 patients were reactive to both PM/Scl-75 and
PM/Scl-100, and 1 patient with sole anti-PM/Scl-75 antibod-
ies also exhibited reactivity to CENP-B (Figure 1c). In overlap
syndromes, 8 out of 9 sera with reactivity to PM/Scl contained
anti-PM/Scl-100 antibodies, including 5 sera showing over-
lapping PM/Scl-75/100 reactivity. Only one patient was exclu-
sively positive for anti-PM/Scl-75 (Figure 1d).
Patients with overlap syndromes showed the highest 
signal strengths for the detection of anti-PM/Scl-75 
antibodies
The signal strengths of anti-PM/Scl-75 antibody-positive
patients appeared to be related to the underlying disease and
were highest in patients with overlap syndromes (Figure 2).
Here, the median signal strength was 92.7 U and the signal
strengths were significantly higher compared with those found
in patients with dSSc, UCTD, or RA. Signal strengths of
greater than 70 U were found in overlap syndromes nearly
exclusively. Only one patient with dSSc who suffered from
muscle pain and muscle atrophy without a detectable eleva-
tion of CK exhibited also a high signal strength of anti-PM/Scl-
75 antibodies. In patients with dSSc and lSSc, the mean sig-
nal strengths were 27.6 and 37 U, respectively. Undifferenti-
ated SSc revealed signal strengths similar to those observed
in lSSc (Figure 2a). In an analysis of the signal strengths for
the detection of anti-PM/Scl-100 antibodies, overlap syn-
dromes did not show the highest values and the different dis-
ease subsets exhibited similar signal strengths (Figure 2b).
Anti-PM/Scl antibodies were associated with muscle 
and lung involvement and were rarely found in patients 
with pulmonary arterial hypertension
In general, patients positive for anti-PM/Scl-75 and/or anti-
PM/Scl-100 antibodies (n = 35) suffered significantly more
frequently from digital ulcers and lung fibrosis compared with
the anti-PM/Scl antibody-negative group (P  = 0.005 and
0.004, respectively). Anti-PM/Scl-positive patients were also
characterized by a higher prevalence of CK elevation (P =
0.002) and a significantly lower frequency of PAH (P = 0.049).
There were no associations between the presence of anti-PM/
Scl antibodies and skin, heart, and kidney involvement as well
as neuropathies or sicca syndrome (data not shown). Patients
with anti-PM/Scl antibodies did not receive more or less immu-
nosuppressants than patients without these antibodies. Fur-
thermore, no differences between antibody-positive and -
negative patients were found by analyzing the gender ratio and
the presence of a family history. No significant associations
Figure 2
Signal strengths of anti-PM/Scl-75 antibodies (a), but not of anti-PM/ Scl-100 antibodies (b), depend on the underlying disease Signal strengths of anti-PM/Scl-75 antibodies (a), but not of anti-PM/
Scl-100 antibodies (b), depend on the underlying disease. Sera from 
patients with diffuse systemic sclerosis (dSSc), limited systemic sclero-
sis (lSSc), overlap syndromes, and undifferentiated systemic sclerosis 
patients were analyzed by line immunoblot assay. PM, polymyositis; RA, 
rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren 
syndrome; U, units; UCTD, undifferentiated connective tissue disease.Arthritis Research & Therapy    Vol 11 No 1    Hanke et al.
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between the presence of anti-PM/Scl antibodies and mortality
could be detected. Four out of 35 SSc patients died (11.4%).
Correlations between the signal strengths of anti-PM/Scl anti-
bodies and the degree of skin or lung fibrosis, mRSS, DLCO-
SB, or FVC were not found (data not shown).
The presence of anti-PM/Scl-75 antibodies identifies a 
distinct subtype of patients
Patients positive for anti-PM/Scl-75 antibodies revealed a sig-
nificantly higher frequency (65.5%) of present or past digital
ulcers compared with anti-PM/Scl-75-negative patients
(37.1%; P = 0.005) (Table 2). Furthermore, the mean mRSS
was considerably higher in the anti-PM/Scl-75-positive
patients (9, standard deviation [SD] 11.3) than in the anti-PM/
Scl-75-negative individuals (5, SD 7.4; P = 0.017). Patients
with anti-PM/Scl-75 antibodies presented a higher prevalence
of lung involvement also. Lung fibrosis could be found in
55.2% of the anti-PM/Scl-75-positive patients but in only
32.7% of the patients without this antibody (P = 0.023). In line
with this, 62.1% of the anti-PM/Scl-75-positive patients suf-
fered from restrictive lung disease, in contrast to 32.3% of the
anti-PM/Scl-75-negative patients (P = 0.001). Furthermore,
significant differences in the mean FVC values were detected
(P < 0.005) by lung function tests. PAH occurred rarely in
patients with PM/Scl-75 reactivity compared with the anti-
body-negative group (P = 0.054). Concerning the involvement
of the musculoskeletal system, anti-PM/Scl-75-positive
patients demonstrated a higher frequency of joint contractures
and muscular atrophy than anti-PM/Scl-75-negative patients
(P = 0.044 and 0.032, respectively). The prevalence of CK
elevation was also higher in the anti-PM/Scl-75-positive group
(P = 0.002). The EUSTAR activity score of anti-PM/Scl-75-
positive patients was significantly higher compared with anti-
PM/Scl-75-negative patients (P = 0.037). The onset of dis-
ease in the anti-PM/Scl-75-positive patients was at a mean
age of 44.2 years (SD 17.6 years), which was 6 years earlier
than in the anti-PM/Scl-75-negative patients (mean age 50.4
years, SD 13.8 years; P = 0.057).
Anti-PM/Scl-100 antibodies were associated with fewer 
gastrointestinal symptoms
Patients with antibodies to PM/Scl-100 (E. coli) revealed a
higher frequency of CK elevation (35%) in comparison with
anti-PM/Scl-100-negative patients (11.5%; P = 0.009) (Table
3). There was only a tendency of an association between the
presence of anti-PM/Scl-100 and the prevalence of lung fibro-
sis (P = 0.086). On the other hand, anti-PM/Scl-100-positive
patients suffered less frequently from gastrointestinal involve-
ments such as diarrhoea, regular emesis, or constipation. For
instance, only 55% of the anti-PM/Scl-100-positive patients
reported episodes of diarrhoea, in contrast to 78.5% of the
negative patients (P = 0.026). When anti-PM/Scl-100 anti-
body-positive and -negative patients were compared, no sig-
nificant differences in the age at disease onset were found
(mean ages of 48.3 and 49.8 years, respectively). Fewer clini-
cal associations were detectable when reactivity to the PM/
Table 2





P value Sensitivity, percentagea Specificity, percentageb
mRSSc 9.0 (11.3) 7.2 (7.4) 0.017 NA NA
Digital ulcersd 19 (65.5) 93 (37.1) 0.005 17 94
Lung fibrosisd 16 (55.2) 82 (32.7) 0.023 16.3 92.9
Restrictive lung diseased 18 (62.1) 81 (32.3) 0.001 18.2 94.8
DLCO-SBc 65.7 (18.1) 73.7 (20.7) 0.091 NA NA
Mean FVCc 80.0 (14.1) 93.6 (19.2) <0.005 NA NA
PAHd 2 (6.9) 58 (23.1) 0.054 3.3 87.7
Contracturesd 23 (79.3) 149 (59.4) 0.044 13.4 94.4
CK elevationd 10 (34.5) 27 (10.8) 0.002 27 92.2
Muscle atrophyd 19 (65.5) 111 (44.2) 0.032 14.6 93.3
Colon involvementd 7(24.1) 112 (44.6) 0.046 5.9 86.3
Disease activityc 2.0 (1.2) 1.5 (1.3) 0.037 NA NA
Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. aProbability 
that patients with the respective disease manifestation are anti-PM/Scl-75-positive; for example, sensitivity of anti-PM/Scl-75 (digital ulcers) = 19/
(19 + 93) = 0.17. bProbability that patients without the respective disease manifestation are anti-PM/Scl-75-negative; for example, specificity of 
anti-PM/Scl-75 (digital ulcers) = (251 - 93)/(29 - 19 + 251 - 93) = 0.94. cValues displayed are medians (standard deviations). dValues displayed 
are numbers of patients (percentages). CK, creatine kinase; DLCO-SB, predicted diffusion capacity of a single breath; FVC, forced vital capacity; 
mRSS, modified Rodnan skin score; NA, not applicable; PAH, pulmonary arterial hypertension.Available online http://arthritis-research.com/content/11/1/R22
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Scl-100 antigen expressed by baculovirus was analyzed.
Here, anti-PM/Scl-100 antibodies were associated only with
an increase in CK (P = 0.043, data not shown).
Discussion
Anti-PM/Scl antibodies are supposed to be a marker for over-
lap syndromes; however, the diagnostic impact of their major
subspecificities, anti-PM/Scl-75 and anti-PM/Scl-100, as well
as their prevalence in different SSc subsets are still not known.
In the present study, a large well-characterized cohort was
analyzed for the presence of the different anti-PM/Scl antibod-
ies.
As shown here, anti-PM/Scl antibodies, in particular anti-PM/
Scl-75, are more frequent than had previously been described
in SSc cohorts. Reactivity to either PM/Scl-100 or PM/Scl-75
was found to depend on the underlying disease subset. Anti-
PM/Scl-75 antibodies are found mostly in patients with dSSc
and overlap syndromes, whereas anti-PM/Scl-100 antibodies
are detected mainly in patients with overlap syndromes. Anti-
PM/Scl antibodies were highly specific for SSc; however, our
analyses did not include patients with primary PM, dermatomy-
ositis, or inclusion body myositis, conditions that could influ-
ence the specificity of the assays.
When the clinical data of the patients were studied, anti-PM/
Scl antibody-positive patients significantly more often showed
muscle involvement and lung fibrosis, confirming other studies
[2,24]. Furthermore, and not described before, digital ulcers
were found to be associated with the presence of anti-PM/Scl
antibodies. In contrast, PAH was less frequently detected in
anti-PM/Scl-positive patients. Anti-PM/Scl-75 antibody-posi-
tive patients were younger at disease onset compared with the
anti-PM/Scl-75-negative patients. In the presence of anti-PM/
Scl-100 antibodies, fewer gastrointestinal symptoms were
found. In view of these findings, detection and distinction of
both antibody specificities appear to be important beyond the
increase in sensitivity for SSc and overlap syndromes.
Only a few studies have analyzed the sensitivity and specificity
of anti-PM/Scl antibodies in large SSc cohorts. One of the first
studies from the Pittsburgh group identified 23 (4%) of 617
patients with connective tissue diseases as being positive for
anti-PM/Scl; this cohort included 314 patients with SSc, 89
patients with overlap syndromes, and 106 patients with pure
dermatomyositis/PM. For the identification of the anti-PM/Scl
antibodies, immunoprecipitation and immunodiffusion were
used. The description of anti-PM/Scl-positive patients
revealed a higher frequency of myositis and a lower incidence
of kidney involvement. There were no differences in the fre-
quency of pulmonary diseases [4]. However, the number of
anti-PM/Scl-positive patients was too small to evaluate signif-
icant differences compared with the antibody-negative group.
Other studies suggested a higher incidence of muscle involve-
ment, confirming studies analyzing myositis patients with or
without SSc overlap [2,7,24,26-28]. Here, we showed the
association between the presence of anti-PM/Scl antibodies
in SSc patients with myositis and with muscle atrophy. In addi-
tion, anti-PM/Scl antibodies are a marker of lung and skin fibro-
sis and of active disease, as previously described also for SSc
patients with anti-topo I antibodies in the same cohort [5,12].
Indeed, a significant proportion of the anti-PM/Scl-positive
patients also exhibited reactivity to the topo I autoantigen
(35.1%). This subgroup of double-positive patients exhibited
higher frequencies of restrictive lung disease (91% versus
46%; P = 0.02) and of contractures (92% versus 59%; P =
0.049) when compared with the anti-PM/Scl single-positive
patients. In this double-positive group, a lower percentage of
patients showed CK elevation (23% versus 36%; P = 0.02)
compared with single-positive patients. In contrast to anti-topo
I antibodies, and probably due to the low number of anti-PM/
Scl-positive patients, there was no increased mortality related
to the signal strengths of the anti-PM/Scl antibodies. How-
ever, 4 out of 29 anti-PM/Scl-75-positive patients (13.8%)
died within 3 years after antibody detection (3 of them were
also positive for anti-topo I antibodies and 2 also exhibited
anti-PM/Scl-100 reactivity) compared with 6.1% in our whole
Table 3





P value Sensitivity, percentagea Specificity, percentageb
Digital ulcersc 12 (60.0) 100 (38.5) 0.095 10.7 95.2
Lung fibrosisc 11 (55.0) 87 (33.5) 0.086 11.2 95.1
CK elevationc 7 (35.0) 30 (11.5) 0.009 18.9 94.7
Esophago-gastral 
involvementc
11 (55.0) 204 (78.5) 0.026 5.1 86.2
Small intestinal 
involvementc
3 (15.0) 100 (38.5) 0.052 2.9 90.4
Colon involvementc 4 (20.0) 115 (44.2) 0.037 3.4 90.1
Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. a,bCalculations 
of sensitivity and specificity are analogous to those in Table 2. cValues displayed are numbers of patients (percentages). CK, creatine kinase.Arthritis Research & Therapy    Vol 11 No 1    Hanke et al.
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SSc cohort. One further patient received autologous stem cell
transplantation. This mortality, the co-incidence with anti-topo
I antibodies, the disease characteristics with a high frequency
of lung fibrosis, and the increased disease activity score espe-
cially in anti-PM/Scl-75-positive patients do not support
former studies claming a milder disease with a favourable
prognosis and response to immunosuppression [5,6].
Here, we could demonstrate for the first time that the reactivity
to PM/Scl depends on the underlying disease and furthermore
on the clinical symptoms. Interestingly, the majority of patients
showed reactivity to only one of the two major autoantigens.
Only 37.1% of anti-PM/Scl-positive patients were double-pos-
itive for both subsets of antibodies. Nevertheless, the higher
prevalence of anti-PM/Scl-75 antibodies and the higher rate of
clinical associations indicate that PM/Scl-75 is the main
autoantigen in SSc patients. Therefore, when tests are used
based on PM/Scl-100 as an antigen source, as most ELISA
and LIA techniques are [3], reactivity to the anti-PM/Scl-75
antigen can be missed, especially in dSSc patients. According
to our results, both specificities should be determined.
Results concerning the main antigenic targets of anti-PM/Scl
antibodies are controversial. Studies analyzing sera from large
myositis cohorts ascribed the highest reactivity to the PM/Scl-
100 autoantigen [26]. However, this finding might be repre-
sentative for myositis patients. In an analysis of sera from dif-
ferent disciplines including SSc patients, the PM/Scl-75,
especially the major isoform PM/Scl-75c, was considered the
main epitope of anti-PM/Scl antibodies [9,10]. Just recently,
the PM/Scl-100 epitope-based ELISA (PM1-alpha) was com-
pared with recombinant PM/Scl-100 and PM/Scl-75c [29].
Thus, further studies are mandatory to address diagnostic
accuracy of the individual PM/Scl antigens.
Furthermore, reactivity to the PM/Scl antigens seems to be
influenced by the system applied for antigen expression. For
the PM/Scl-100 antigen, the baculovirus expression system
did not provide additional benefit when compared with the E.
coli expression system. Therefore, post-translational modifica-
tions made by eucaryotic cells do not appear to play a role in
anti-PM/Scl-100 antibody binding. Consequently, the PM/Scl-
100 antigen can be produced using the E. coli expression sys-
tem as an easy and cost-effective method [30,31].
In summary, this is the first report about the prevalence of dif-
ferent anti-PM/Scl antibodies in SSc patients classified and
assessed by the commonly used standards of the DNSS and
EUSTAR network. Antibodies against PM/Scl-75 and PM/Scl-
100 can be considered independent markers for different SSc
subsets and show partial differences with respect to associ-
ated clinical manifestations, substantiating the diagnostic rele-
vance of their parallel determination.
Conclusion
The prevalence of anti-PM/Scl-75 and anti-PM/Scl-100 anti-
bodies depends on the underlying SSc subsets and the
patients' clinical manifestations. Their presence is not associ-
ated with a favourable outcome, especially in the presence of
anti-PM/Scl-75 antibodies. Patients with dSSc show reactivity
directed mainly to the PM/Scl-75 autoantigen, whereas over-
lap syndromes can reveal reactivity to PM/Scl-75 and PM/Scl-
100. A major proportion of SSc patients might remain unde-
tected when applied tests are limited to the detection of anti-
PM/Scl-100 antibodies.
Competing interests
GR has received fees from EUROIMMUN AG for lectures on
these data at the 'Eurodoctor' meeting in Brussels, Belgium.
KH was invited by EUROIMMUN AG to participate in a
national meeting to show the results of the study. After finish-
ing the study, she received a grant from EUROIMMUN AG for
additional scientific work. The other authors declare that they
have no competing interests.
Authors' contributions
KH and AK helped to provide preclinical analyses, statistics,
and graphics and to write the manuscript. CD, AJ, LK, and WM
helped to develop the LIA and to perform the tests. M Back-
haus provided access to the patients in her outpatient depart-
ment. CSB helped to provide clinical data. M Becker
corrected and helped to write the manuscript. DH supervised
statistical analyses. KE participated in discussions of the data
with GR, made intellectual contributions, helped to prepare
the manuscript, and provided sera for the analyses. GRB and
FH participated in discussions of the data with GR, made intel-
lectual contributions, and helped to prepare the manuscript.
WS organized all of the cooperation with EUROIMMUN AG
and made intellectual contributions. GR, as the author respon-
sible for this report, initiated this study and controlled the work.
She collected and assessed the patients, helped to provide
clinical data, and wrote and reviewed the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This study was supported by the BMBF (Bundesministerium für Bildung 
und Forschung)-sponsored German Network of Systemic Sclerosis 
(BMBF Fkz 01 GM 0310 [C2, C6, TP6]) and by the European Sclero-
derma Trials and Research network. EUROIMMUN AG has performed 
the antibody detection without any knowledge of the clinical data. The 
authors thank Michael Mahler and Marvin J Fritzler for their advice.
References
1. Reichlin M, Maddison PJ, Targoff I, Bunch T, Arnett F, Sharp G,
Treadwell E, Tan EM: Antibodies to a nuclear/nucleolar antigen
in patients with polymyositis overlap syndromes.  J Clin Immu-
nol 1984, 4:40-44.
2. Steen VD: Autoantibodies in systemic sclerosis.  Semin Arthritis
Rheum 2005, 35:35-42.
3. Mahler M, Raijmakers R: Novel aspects of autoantibodies to the
PM/Scl complex: clinical, genetic and diagnostic insights.
Autoimmun Rev 2007, 6:432-437.Available online http://arthritis-research.com/content/11/1/R22
Page 9 of 9
(page number not for citation purposes)
4. Oddis CV, Okano Y, Rudert WA, Trucco M, Duquesnoy RJ, Meds-
ger TA Jr: Serum autoantibody to the nucleolar antigen PM-Scl.
Clinical and immunogenetic associations.  Arthritis Rheum
1992, 35:1211-1217.
5. Marguerie C, Bunn CC, Copier J, Bernstein RM, Gilroy JM, Black
CM, So AK, Walport MJ: The clinical and immunogenetic fea-
tures of patients with autoantibodies to the nucleolar antigen
PM-Scl.  Medicine (Baltimore) 1992, 71:327-336.
6. Vandergheynst F, Ocmant A, Sordet C, Humbel RL, Goetz J, Rou-
fosse F, Cogan E, Sibilia J: Anti-pm/scl antibodies in connective
tissue disease: clinical and biological assessment of 14
patients.  Clin Exp Rheumatol 2006, 24:129-133.
7. Alderuccio F, Chan EK, Tan EM: Molecular characterization of
an autoantigen of PM-Scl in the polymyositis/scleroderma
overlap syndrome: a unique and complete human cDNA
encoding an apparent 75-kD acidic protein of the nucleolar
complex.  J Exp Med 1991, 173:941-952.
8. Blüthner M, Bautz FA: Cloning and characterization of the cDNA
coding for a polymyositis-scleroderma overlap syndrome-
related nucleolar 100-kD protein.  J Exp Med 1992,
176:973-980.
9. Raijmakers R, Renz M, Wiemann C, Egberts WV, Seelig HP, van
Venrooij WJ, Pruijn GJ: PM-Scl-75 is the main autoantigen in
patients with the polymyositis/scleroderma overlap syn-
drome.  Arthritis Rheum 2004, 50:565-569.
10. Raijmakers R, Egberts WV, van Venrooij WJ, Pruijn GJ: The asso-
ciation of the human PM/Scl-75 autoantigen with the exo-
some is dependent on a newly identified N terminus.  J Biol
Chem 2003, 278:30698-30704.
11. Mahler M, Raijmakers R, Dähnrich C, Blüthner M, Fritzler MJ: Clin-
ical evaluation of autoantibodies to a novel PM/Scl peptide
antigen.  Arthritis Res Ther 2005, 7:R704-713.
12. Hanke K, Dahnrich C, Bruckner C, Huscher D, Becker M, Janssen
A, Meyer W, Egerer K, Hiepe F, Burmester G R, Schlumberger W,
Riemekasten G: Diagnostic value of anti-topoisomerase I anti-
bodies in a large monocentric cohort.  Arthritis Res Ther 2009,
11:R28.
13. Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-
Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M:
Clinical risk assessment of organ manifestations in systemic
sclerosis: a report from the EULAR Scleroderma Trials And
Research group database.  Ann Rheum Dis 2007, 66:754-763.
14. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I,
Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten
G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus
P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-
Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller
A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, et
al.:  Registry of the German Network for Systemic Sclero-
derma. The registry of the German Network for Systemic Scle-
roderma: frequency of disease subsets and patterns of organ
involvement.  Rheumatology (Oxford) 2008, 47:1185-1192.
15. Czirják L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M,
Furst DE, EUSTAR: The EUSTAR model for teaching and imple-
menting the modified Rodnan skin score in systemic sclerosis.
Ann Rheum Dis 2007, 66:966-969.
16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger
TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis):
classification, subsets and pathogenesis.  J Rheumatol 1988,
15:202-205.
17. Bennett RM: Scleroderma overlap syndrome.  Rheum Dis Clin
North Am 1990, 16:185-198.
18. Rodnan GP, Fennel RH Jr: Progressive systemic sclerosis sine
scleroderma.  JAMA 1962, 180:665-670.
19. Mosca M, Neri R, Bombardieri S: Undifferentiated connective
tissue diseases (UCTD): a review of the literature and a pro-
posal for preliminary classification criteria.  Clin Exp Rheumatol
1999, 17:615-620.
20. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Benciv-
elli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, de Vita S,
Drosos AA, Ehrenfeld M, Hatron PY, Hay EM, Isenberg DA, Janin
A, Kalden JR, Kater L, Konttinen YT, Maddison PJ, Maini RN, Man-
thorpe R, Meyer O, Ostuni P, Pennec Y, Prause JU, Richards A,
Sauvezie B, Schiødt M, Sciuto M, et al.: Preliminary criteria for
the classification of Sjögren's syndrome. Results of a prospec-
tive concerted action supported by the European Community.
Arthritis Rheum 1993, 36:340-347.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF,
Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for
the classification of systemic lupus erythematosus.  Arthritis
Rheum 1982, 25:1271-1277.
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr,
Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT,
Wilder RL, Hunder GG: The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthri-
tis.  Arthritis Rheum 1988, 31:315-324.
23. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT,
D'Angelo WA, Lachenbruch PA, Grau RG, Seibold JR: The mod-
ified Rodnan skin score is an accurate reflection of skin biopsy
thickness in systemic sclerosis.  J Rheumatol 1998, 25:84-88.
24. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa
A, Silman AJ, Black CM, Czirjak L, Nielsen H, Vlachoyiannopoulos
PG: European Scleroderma Study Group to define disease
activity criteria for systemic sclerosis. III. Assessment of the
construct validity of the preliminary activity criteria.  Ann
Rheum Dis 2003, 62:901-903.
25. Blüthner M, Mahler M, Müller DB, Dünzl H, Bautz FA: Identifica-
tion of an alpha-helical epitope region on the PM/Scl-100
autoantigen with structural homology to a region on the hete-
rochromatin p25beta autoantigen using immobilized overlap-
ping synthetic peptides.  J Mol Med 2000, 78:47-54.
26. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R,
Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M: Myosi-
tis-specific and myositis-associated antibodies in a series of
eighty-eight Mediterranean patients with idiopathic inflamma-
tory myopathy.  Arthritis Rheum 2006, 55:791-798.
27. Brouwer R, Vree Egberts WT, Hengstman GJ, Raijmakers R, van
Engelen BG, Seelig HP, Renz M, Mierau R, Genth E, Pruijn GJ, van
Venrooij WJ: Autoantibodies directed to novel components of
the PM/Scl complex, the human exosome.  Arthritis Res 2002,
4:134-138.
28. Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B,
Ghirardello A, Grøndal G, Hietarinta M, Isenberg D, Kalden JR,
Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wik-
man A, Seelig HP, van Engelen BG, van Venrooij WJ: Autoanti-
body profiles in the sera of European patients with myositis.
Ann Rheum Dis 2001, 60:116-123.
29. Mahler M, Mierau R, Humbel RL, Fritzler MJ: Anti-PM1-alpha anti-
bodies: analytical evaluation in two centers.  Paper presented
at: 6th International Congress on Autoimmunity; 10–14 Septem-
ber 2008; Porto, Portugal. 
30. Schmidt M, Hoffman DR: Expression systems for production of
recombinant allergens.  Int Arch Allergy Immunol 2002,
128:264-270.
31. Hu YC: Baculovirus as a highly efficient expression vector in
insect and mammalian cells.  Acta Pharmacol Sin 2005,
26:405-416. Review